Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 59

1.

Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations.

Wik E, Trovik J, Kusonmano K, Birkeland E, Raeder MB, Pashtan I, Hoivik EA, Krakstad C, Werner HM, Holst F, Mjøs S, Halle MK, Mannelqvist M, Mauland KK, Oyan AM, Stefansson IM, Petersen K, Simon R, Cherniack AD, Meyerson M, Kalland KH, Akslen LA, Salvesen HB.

Gynecol Oncol. 2014 Jul 1. pii: S0090-8258(14)01067-1. doi: 10.1016/j.ygyno.2014.06.026. [Epub ahead of print]

PMID:
24995579
[PubMed - as supplied by publisher]
2.

High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors.

Engerud H, Tangen IL, Berg A, Kusonmano K, Halle MK, Oyan AM, Kalland KH, Stefansson I, Trovik J, Salvesen HB, Krakstad C.

Br J Cancer. 2014 Jul 1;111(1):78-84. doi: 10.1038/bjc.2014.262. Epub 2014 May 22.

PMID:
24853175
[PubMed - in process]
3.

Switch in FOXA1 status associates with endometrial cancer progression.

Tangen IL, Krakstad C, Halle MK, Werner HM, Oyan AM, Kusonmano K, Petersen K, Kalland KH, Akslen LA, Trovik J, Hurtado A, Salvesen HB.

PLoS One. 2014 May 21;9(5):e98069. doi: 10.1371/journal.pone.0098069. eCollection 2014.

PMID:
24849812
[PubMed - in process]
Free PMC Article
4.

Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.

Hoivik EA, Kusonmano K, Halle MK, Berg A, Wik E, Werner HM, Petersen K, Oyan AM, Kalland KH, Krakstad C, Trovik J, Widschwendter M, Salvesen HB.

Oncotarget. 2014 Feb 28;5(4):1052-61.

PMID:
24658009
[PubMed - in process]
Free PMC Article
5.

Spontaneous reversion of the angiogenic phenotype to a nonangiogenic and dormant state in human tumors.

Rogers MS, Novak K, Zurakowski D, Cryan LM, Blois A, Lifshits E, Bø TH, Oyan AM, Bender ER, Lampa M, Kang SY, Naxerova K, Kalland KH, Straume O, Akslen LA, Watnick RS, Folkman J, Naumov GN.

Mol Cancer Res. 2014 May;12(5):754-64. doi: 10.1158/1541-7786.MCR-13-0532-T. Epub 2014 Feb 26.

PMID:
24574516
[PubMed - in process]
6.

Generation of prostate tumor-initiating cells is associated with elevation of reactive oxygen species and IL-6/STAT3 signaling.

Qu Y, Oyan AM, Liu R, Hua Y, Zhang J, Hovland R, Popa M, Liu X, Brokstad KA, Simon R, Molven A, Lin B, Zhang WD, McCormack E, Kalland KH, Ke XS.

Cancer Res. 2013 Dec 1;73(23):7090-100. doi: 10.1158/0008-5472.CAN-13-1560. Epub 2013 Oct 7.

PMID:
24101153
[PubMed - indexed for MEDLINE]
7.

Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients.

Reikvam H, Øyan AM, Kalland KH, Hovland R, Hatfield KJ, Bruserud Ø.

Cell Prolif. 2013 Oct;46(5):554-62. doi: 10.1111/cpr.12057.

PMID:
24073609
[PubMed - indexed for MEDLINE]
8.

p63 attenuates epithelial to mesenchymal potential in an experimental prostate cell model.

Olsen JR, Oyan AM, Rostad K, Hellem MR, Liu J, Li L, Micklem DR, Haugen H, Lorens JB, Rotter V, Ke XS, Lin B, Kalland KH.

PLoS One. 2013 May 1;8(5):e62547. doi: 10.1371/journal.pone.0062547. Print 2013.

PMID:
23658742
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition.

Wik E, Birkeland E, Trovik J, Werner HM, Hoivik EA, Mjos S, Krakstad C, Kusonmano K, Mauland K, Stefansson IM, Holst F, Petersen K, Oyan AM, Simon R, Kalland KH, Ricketts W, Akslen LA, Salvesen HB.

Clin Cancer Res. 2013 May 1;19(9):2331-41. doi: 10.1158/1078-0432.CCR-12-3413. Epub 2013 Mar 28.

PMID:
23538402
[PubMed - indexed for MEDLINE]
Free Article
10.

Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers.

Raeder MB, Birkeland E, Trovik J, Krakstad C, Shehata S, Schumacher S, Zack TI, Krohn A, Werner HM, Moody SE, Wik E, Stefansson IM, Holst F, Oyan AM, Tamayo P, Mesirov JP, Kalland KH, Akslen LA, Simon R, Beroukhim R, Salvesen HB.

PLoS One. 2013;8(2):e54873. doi: 10.1371/journal.pone.0054873. Epub 2013 Feb 5.

PMID:
23393560
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

MiR-182 and miR-203 induce mesenchymal to epithelial transition and self-sufficiency of growth signals via repressing SNAI2 in prostate cells.

Qu Y, Li WC, Hellem MR, Rostad K, Popa M, McCormack E, Oyan AM, Kalland KH, Ke XS.

Int J Cancer. 2013 Aug 1;133(3):544-55. doi: 10.1002/ijc.28056. Epub 2013 Feb 27.

PMID:
23354685
[PubMed - indexed for MEDLINE]
12.

Lack of estrogen receptor-α is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma.

Wik E, Ræder MB, Krakstad C, Trovik J, Birkeland E, Hoivik EA, Mjos S, Werner HM, Mannelqvist M, Stefansson IM, Oyan AM, Kalland KH, Akslen LA, Salvesen HB.

Clin Cancer Res. 2013 Mar 1;19(5):1094-105. doi: 10.1158/1078-0432.CCR-12-3039. Epub 2013 Jan 14.

PMID:
23319822
[PubMed - indexed for MEDLINE]
Free Article
13.

High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated.

Krakstad C, Birkeland E, Seidel D, Kusonmano K, Petersen K, Mjøs S, Hoivik EA, Wik E, Halle MK, Øyan AM, Kalland KH, Werner HM, Trovik J, Salvesen H.

PLoS One. 2012;7(12):e52795. doi: 10.1371/journal.pone.0052795. Epub 2012 Dec 27.

PMID:
23300780
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.

Birkeland E, Wik E, Mjøs S, Hoivik EA, Trovik J, Werner HM, Kusonmano K, Petersen K, Raeder MB, Holst F, Øyan AM, Kalland KH, Akslen LA, Simon R, Krakstad C, Salvesen HB.

Br J Cancer. 2012 Dec 4;107(12):1997-2004. doi: 10.1038/bjc.2012.477. Epub 2012 Oct 25.

PMID:
23099803
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas.

Werner HM, Berg A, Wik E, Birkeland E, Krakstad C, Kusonmano K, Petersen K, Kalland KH, Oyan AM, Akslen LA, Trovik J, Salvesen HB.

Mod Pathol. 2013 Mar;26(3):428-34. doi: 10.1038/modpathol.2012.174. Epub 2012 Oct 19.

PMID:
23080032
[PubMed - indexed for MEDLINE]
Free Article
16.

Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer.

Straume O, Shimamura T, Lampa MJ, Carretero J, Øyan AM, Jia D, Borgman CL, Soucheray M, Downing SR, Short SM, Kang SY, Wang S, Chen L, Collett K, Bachmann I, Wong KK, Shapiro GI, Kalland KH, Folkman J, Watnick RS, Akslen LA, Naumov GN.

Proc Natl Acad Sci U S A. 2012 May 29;109(22):8699-704. doi: 10.1073/pnas.1017909109. Epub 2012 May 15.

PMID:
22589302
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Lipocalin 2 expression is associated with aggressive features of endometrial cancer.

Mannelqvist M, Stefansson IM, Wik E, Kusonmano K, Raeder MB, Øyan AM, Kalland KH, Moses MA, Salvesen HB, Akslen LA.

BMC Cancer. 2012 May 6;12:169. doi: 10.1186/1471-2407-12-169.

PMID:
22559235
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome.

Krakstad C, Trovik J, Wik E, Engelsen IB, Werner HM, Birkeland E, Raeder MB, Øyan AM, Stefansson IM, Kalland KH, Akslen LA, Salvesen HB.

Br J Cancer. 2012 May 8;106(10):1682-8. doi: 10.1038/bjc.2012.91. Epub 2012 Mar 13.

PMID:
22415229
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Gene expression in tumor cells and stroma in dsRed 4T1 tumors in eGFP-expressing mice with and without enhanced oxygenation.

Moen I, Jevne C, Wang J, Kalland KH, Chekenya M, Akslen LA, Sleire L, Enger PØ, Reed RK, Øyan AM, Stuhr LE.

BMC Cancer. 2012 Jan 17;12:21. doi: 10.1186/1471-2407-12-21.

PMID:
22251838
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer.

Mauland KK, Trovik J, Wik E, Raeder MB, Njølstad TS, Stefansson IM, Oyan AM, Kalland KH, Bjørge T, Akslen LA, Salvesen HB.

Br J Cancer. 2011 Mar 15;104(6):921-6. doi: 10.1038/bjc.2011.46. Epub 2011 Feb 22.

PMID:
21343929
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk